Security
CMPX · Compass Therapeutics, Inc.
CMPXNASDAQCommon stockCurrentCIK 1738021Updated Sep 29, 2026
Name history
Olivia Ventures, Inc. · through Jun 8, 2020
CMPX price & chart
Loading TradingView…
NASDAQ:CMPX on TradingView ↗About the company
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts.
In the news
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX ↗
Recent filings
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13G/A filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 219,588,000Source | 140,403,000Source | 156,875,000Source | 199,645,000Source |
| Property, Plant and Equipment, NetUSD | 102,000Source | 353,000Source | 898,000Source | 1,567,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 30,643,000Source | 43,483,000Source | 24,228,000Source | 34,946,000Source |
| Assets, CurrentUSD | 209,819,000Source | 132,751,000Source | 153,881,000Source | 194,791,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 913,000Source | 6,029,000Source | 1,420,000Source | 8,182,000Source |
| Operating Lease, Right-of-Use AssetUSD | 9,099,000Source | 6,731,000Source | 1,776,000Source | 2,967,000Source |
| Other Assets, NoncurrentUSD | — | 568,000Source | 320,000Source | 320,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 22,797,000Source | 15,170,000Source | 8,337,000Source | 18,007,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 18,000Source | 14,000Source | 13,000Source | 13,000Source |
| Retained Earnings (Accumulated Deficit)USD | -431,172,000Source | -364,683,000Source | -315,308,000Source | -272,814,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 280,000Source | 210,000Source | 37,000Source | -302,000Source |
| Stockholders' Equity Attributable to ParentUSD | 196,791,000Source | 125,233,000Source | 148,538,000Source | 181,638,000Source |
| Additional Paid in Capital, Common StockUSD | 627,665,000Source | 489,692,000Source | 463,796,000Source | 454,741,000Source |
| Liabilities and EquityUSD | 219,588,000Source | 140,403,000Source | 156,875,000Source | 199,645,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 13,968,000Source | 8,874,000Source | 7,801,000Source | 16,169,000Source |
| Operating Lease, Liability, CurrentUSD | 1,000,000Source | 338,000Source | 1,197,000Source | 1,097,000Source |
| Accounts Payable, CurrentUSD | 1,585,000Source | 2,249,000Source | 4,090,000Source | 3,382,000Source |
| Operating Lease, Liability, NoncurrentUSD | 8,829,000Source | 6,296,000Source | 536,000Source | 1,838,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 11,383,000Source | 6,287,000Source | 2,514,000Source | 11,690,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,368,000Source | 8,560,000Source | 6,120,000Source | 5,330,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -664,000Source | -1,841,000Source | 708,000Source | 2,515,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -49,143,000Source | -44,855,000Source | -40,618,000Source | -34,125,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -93,306,000Source | 46,772,000Source | 26,965,000Source | -151,200,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 25,000Source | 44,000Source | 30,000Source | 212,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,027,000Source | 232,000Source | 159,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 129,609,000Source | 17,338,000Source | 2,935,000Source | 75,757,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -12,840,000Source | 19,255,000Source | -10,718,000Source | -109,568,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 31,211,000Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 0Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 8,368,000Source | 8,560,000Source | 6,120,000Source | 5,330,000Source |
| DepreciationUSD | 300,000Source | 600,000Source | 700,000Source | 800,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | 70,000Source |
| General and Administrative ExpenseUSD | 16,870,000Source | 15,133,000Source | 12,243,000Source | 11,658,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 6,400,000Source | 7,300,000Source | 7,869,000Source | 2,360,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 70,000Source | -173,000Source | -339,000Source | 302,000Source |
| Net Income (Loss) Attributable to ParentUSD | -66,489,000Source | -49,375,000Source | -42,494,000Source | -39,225,000Source |
| Operating ExpensesUSD | 72,839,000Source | 57,475,000Source | 50,363,000Source | 41,655,000Source |
| Other Nonoperating Income (Expense)USD | 6,350,000Source | 7,250,000Source | 7,869,000Source | 2,430,000Source |
| Proceeds from Issuance of Common StockUSD | 137,999,000Source | 18,113,000Source | 3,126,000Source | 76,237,000Source |
| Proceeds from Stock Options ExercisedUSD | 1,275,000Source | 0Source | 62,000Source | 15,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | 850,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -72,839,000Source | -56,625,000Source | -50,363,000Source | -41,655,000Source |
| Other Nonoperating Income (Expense)USD | 6,350,000Source | 7,250,000Source | 7,869,000Source | 2,430,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -42,494,000Source | -39,225,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -66,489,000Source | -49,375,000Source | -42,494,000Source | -39,225,000Source |
| Earnings Per Share, BasicUSD per share | -0.42Source | -0.36Source | -0.33Source | -0.37Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 157,695,000Source | 137,384,000Source | 127,027,000Source | 105,186,000Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 276,000Source | 589,000Source | 699,000Source | 782,000Source |
| General and Administrative ExpenseUSD | 16,870,000Source | 15,133,000Source | 12,243,000Source | 11,658,000Source |
| Interest ExpenseUSD | — | — | — | 0Source |
| Investment Income, InterestUSD | 6,400,000Source | 7,300,000Source | 7,869,000Source | 2,360,000Source |
| Operating ExpensesUSD | 72,839,000Source | 57,475,000Source | 50,363,000Source | 41,655,000Source |
| Research and Development ExpenseUSD | 55,969,000Source | 42,342,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 0Source | 850,000Source | — | — |
Filing attachments
d153873dex41.htm · 8-K · 2025-08-13
EX-4.1 3 d153873dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2025 COMPASS THERAPEUTICS, INC. Compass Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to …
Read attachment ↗d153873dex991.htm · 8-K · 2025-08-13
EX-99.1 5 d153873dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Compass Therapeutics Announces Proposed Public Offering BOSTON, August 12, 2025 - Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants …
Read attachment ↗d153873dex992.htm · 8-K · 2025-08-13
EX-99.2 6 d153873dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering BOSTON, August 12, 2025 - Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public o…
Read attachment ↗